Welcome to the official InxMed website

OUR SCIENCE

Priming tumor microenvironment with regimen,killing cancer cells and consolidating treatment via specified therapy

R&D PIPELINE

xin

Time of issue:2023-02-21 16:41:00

 

Asset Modality / Target Regimen Indication Discovery Pre-Clinical FIH POC Pivotal
IN10018         Small molecular FAK inhibitor + PLD  PROC (double-blind, placebo controlled, randomized study)
 
+ MEKi ± IO IO-failed NRAS melanoma Uveal melanoma
 
+ PLD ± IO PROC, TNBC, HNSCC
 
+ chemotherapy + IO IO-failed NSCLC (randomized study)
 
+ chemotherapy + IO bispecific Pancreatic cancer
 
+ KRASG12C inhibitor KRASG12CCRC and NSCLC
 
+3rd EGFR inhibitor EGFR mutant NSCLC
 
OMTX705 ADC Targeting FAP Mono / Combo Solid Tumor
 
INES103 Antibody Target undisclosed Combo Solid Tumor
 
IN30718 ADC Target undisclosed Mono Solid Tumor
 
IN30728 ADC Target undisclosed Mono Solid Tumor
 
IN20019 Small molecular Target undisclosed Mono Solid Tumor
 

LATEST NEWS

InxMed
2023-12-20

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

Nanjing, China, Dec 20, 2023 -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens (TAAs) targeting ADCs.  
白箭头
InxMed
2023-10-25

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 23, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in platinum-resistant recurrent ovarian cancer (PROC)and triple-negative breast cancer(TNBC)has been presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid,Spain.
白箭头
InxMed
2023-10-19

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

NANJING, China, Oct 19, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for hard-to-treat solid tumors, is presenting preclinical data at 14th Annual World ADC Conference in San Diego regarding IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to boost efficacy of ADCs, and IN30718,a First-in-Class cancer associated fibroblast (CAF) targeting ADC for high stroma tumors.
白箭头
BioWorld:Inxmed
2022-03-17

BioWorld:Inxmed raises $50M to develop cancer therapy in the US, China

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.
白箭头
Dialogue
2019-06-20

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.
白箭头
Freehand
2019-07-29

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"
白箭头
 InxMed

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO